Get started

Healthcare

CHFS CHF-Solutions ER Report WILL IT FILL THE GAP? This needs volume to fill the gap. Not Much news out. Think or swim Calendar says ER is the 15th of March Meeting with investors is on the 18th, saw a decent Roth Conference Slideshow, and they just had an inducement grant approved and I believe there was insider stock purchase a month or two ago. The company will meet with investors throughout the day on Tuesday, March 13, 2018 at The Ritz Carlton, Laguna Niguel, Orange County, Ca. John L. Erb is CEO...Please do your DD but my opinion is this thing has a nice POP coming. Please give any feedback. Good or Bad. Market Capitalization $6.44M $12.97B 9th Total Return (1 Year Annualized) AS OF 03/08/2018 -95.35 24.64 -- Beta (1 Year Annualized) 0.63 0.97 91st EPS (TTM) AS OF 09/30/2017 $-115.40 $0.56 2nd Current Consensus EPS Estimate $-1.26 -- -- EPS Growth (TTM vs. Prior TTM) +79.32% +10.48% 88th P/E (TTM) AS OF 03/09/2018 NM 74.14 -- Dividend Yield (Annualized) -- -- -- Total Revenue (TTM) AS OF 09/30/2017 $3.47M $12.85B 29th Revenue Growth (TTM vs Prior TTM) +538.67% +17.36% 100th Shares Outstanding 1,799,000 649,075,968 3rd Institutional Ownership 26.40% 81.26% 39th
C
by nobodee
1
INSY Target $23 FDA Cannabidiol Fast trackFDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder characterized by insatiable appetite in children that often leads to obesity and type 2 diabetes. “FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, a debilitating condition which currently does not have any approved products available,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. “We plan to start the clinical development program for this promising therapy in late first quarter of 2018.” The most common known genetic cause of life-threatening obesity in children, Prader-Willi syndrome has a prevalence of approximately 1 in 15,000, according to the Prader-Willi Syndrome Association, occurring in males and females equally and in all races. “We are very encouraged by the FDA’s decision to put CBD for Prader-Willi on the Fast Track and believe it is good news for these young patients, their families and clinicians,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “This special regulatory designation represents a significant milestone in the company’s R&D program, which is focused on developing and delivering safe, effective and novel treatment options using cannabinoids and novel drug delivery technology for unmet medical needs.” About INSYS INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. Forward-Looking Statements This news release contains forward-looking statements including regarding (i) our belief that FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, (ii) our belief that Prader-Willi syndrome currently does not have any approved products available and that our proprietary CBD formulation has potential to be a viable treatment option and (iii) our plan to start the clinical development program for this promising therapy in late first quarter of 2018. These forward-looking statements are based on management’s expectations and assumptions as of the date of this news release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to, risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2016 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this news release, and we undertake no obligation to publicly update or revise these statements, except as may be required by law.
ILong
by StockPicksNYC98
October 26 Earnings: Gilead - Flying the KiteGilead's core product pipeline, including recent FDA approval is set to soar as key drugs and generics are continuing to outperform. The company's recent acquisition of KITE Pharma came at the perfect moment with KITE being granted a key drug approval by the FDA. Gilead's recent cost cutting efforts and R&D focus are to further push growth prospect and boost overall FY guidance. Generic competition will continue to weigh, however, and limit some blockbuster drug expansion. I'm starting Gilead with a $90 PT for an extended post-earnings move. A S/L at $75 around recent area is advised.
NASDAQ:GILDLong
by TraderDanER
CVS, waiting for the breakoutThe stock is moving in a sideways parallel channel started at the beginning of 2017. This movement can be a redistribution or an accumulation phase, it depends if it breaks lower or higher. If the price breaks lower the minimum target is around 70 and if it breaks higher the minimum target is around 88. The breakout must be confirmed by very high volume to avoid fakeouts or pullbacks. The informations and the strategies discussed are NOT recommendation to buy, sell or trade any securities. They are strictly for educational and illustrative purposes.
NYSE:CVS
by UnknownUnicorn1249598
PTOY LONG HODL Get it while it's hot!This company is going places, I have been researching the team, the fundamentals, and TA for about a week or two for a few hours every day. The entirety of the staff checks out and they have built a HIPPA approved platform to interface with EMR companies. This will revolutionize healthcare as we know it, they have a free app coming out this month for patients to interface with their care team as well as other individuals with similar conditions. They have been chosen to present at a convention in Atlanta October 2017, have been picked multiple times in multiple places one of the top ten most influential companies, not even at events solely restricted to the crypto space...top ten out of hundreds of other companies. This will disrupt healthcare IT as we know it! They are also doing a trial at 8 hospitals for ninety days. This will climb throughout that time and if even one of those 8 hospitals signs on after the 90 day trial that will send it flying. I have connections in the healthcare space, (specifically pharmaceuticals and EMR) and I have showed them this company and their plan of action and they agree that it is a winner. Oh did I mention they are HIPPA compliant, yes I did, but that is HUGE. My understanding is that they can interface with current EMR companies as well as having the technology to possibly replace them down the road. My understanding is they are also aligned with Kaiser Permanente which is almost enough right there. If you have a little more time than I have taken already there is a great analysis on medium that I cannot take credit for. medium.com Writing this I feel like a schill but this is far from the truth, I have bought in 3x and plan to as much more as I can, my family is and my friends are. This one is a win that I may not ever let go of.
Long
by Uptrender2ThePhlow
3
A Low Beta Way to Play Biopharma IndustryAttached is a piece about SWKH in which I discuss the value within the company, and I suggest it as a way of exposure to the healthcare technology sector without the risk. How is that possible? SWKH uses debt investments when making acquisitions in companies. Debt investments are usually the first investments to be paid back in full when a company undergoes liquidation / bankruptcy. Give it a read and let me know what y'all think. rockvuecapital.wordpress.com All the best, RC
SLong
by BrandonBeylo